Brown Advisory Inc Vertex Pharmaceuticals Inc Transaction History

Brown Advisory Inc

$77.3 Billion
Q3 2024

A detailed history of Brown Advisory Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Brown Advisory Inc holds 5,201 shares of VRTX stock, worth $2.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,201

Previous 5,195 0.12%

Holding current value

$2.35 Million

Previous $2.44 Million 0.7%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$460.0 - $505.78 $2,760 - $3,034	6 Added 0.12%	5,201 $2.42 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $175,193 - $216,546	446 Added 9.39%	5,195 $2.44 Million
Q1 2024 Apr 24, 2024	BUY	$407.69 - $446.08 $500,235 - $547,340	1,227 Added 34.84%	4,749 $1.99 Million
Q4 2023 Feb 08, 2024	BUY	$343.0 - $410.68 $241,815 - $289,529	705 Added 25.03%	3,522 $1.43 Million
Q3 2023 Oct 24, 2023	BUY	$338.18 - $362.46 $22,658 - $24,284	67 Added 2.44%	2,817 $979,000
Q2 2023 Jul 31, 2023	BUY	$314.42 - $351.91 $62,569 - $70,030	199 Added 7.8%	2,750 $967,000
Q1 2023 May 08, 2023	BUY	$283.23 - $323.1 $93,465 - $106,623	330 Added 14.86%	2,551 $803,000
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $67,725 - $76,190	237 Added 11.95%	2,221 $641,000
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $51,206 - $57,134	187 Added 10.41%	1,984 $574,000
Q2 2022 Nov 14, 2022	SELL	$234.96 - $292.55 $28,430 - $35,398	-121 Reduced 6.31%	1,797 $507,000
Q2 2022 Aug 02, 2022	BUY	$234.96 - $292.55 $13,392 - $16,675	57 Added 4.58%	1,301 $367,000
Q1 2022 Nov 14, 2022	BUY	$221.42 - $260.97 $136,616 - $161,018	617 Added 47.43%	1,918 $501,000
Q1 2022 May 09, 2022	SELL	$221.42 - $260.97 $8,856 - $10,438	-40 Reduced 3.12%	1,244 $325,000
Q4 2021 Jan 27, 2022	SELL	$177.01 - $223.45 $41,597 - $52,510	-235 Reduced 15.47%	1,284 $282,000
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $96,862 - $108,396	-534 Reduced 26.01%	1,519 $276,000
Q2 2021 Jul 29, 2021	BUY	$187.49 - $221.1 $101,994 - $120,278	544 Added 36.05%	2,053 $413,000
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $18,217 - $21,235	88 Added 6.19%	1,509 $325,000
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $121,514 - $162,064	-587 Reduced 29.23%	1,421 $336,000
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $96,635 - $114,571	378 Added 23.19%	2,008 $546,000
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $367,532 - $482,154	1,630 New	1,630 $473,000
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $203,765 - $252,766	-1,020 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $170,044 - $228,388	1,020 New	1,020 $223,000
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $239,204 - $269,222	-1,439 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$164.61 - $190.37 $840,992 - $972,600	-5,109 Reduced 78.02%	1,439 $263,000
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $24,068 - $28,620	147 Added 2.3%	6,548 $1.2 Million
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $10,481 - $13,262	69 Added 1.09%	6,401 $1.06 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $838 - $963	5 Added 0.08%	6,332 $1.22 Million
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $44,298 - $51,667	304 Added 5.05%	6,327 $1.08 Million
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $45,176 - $52,784	-298 Reduced 4.71%	6,023 $981,000
Q4 2017 Feb 12, 2018	BUY	$137.28 - $155.55 $27,456 - $31,110	200 Added 3.27%	6,321 $948,000
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $2,814 - $3,082	19 Added 0.31%	6,121 $931,000
Q2 2017 Aug 14, 2017	BUY	N/A	6,102	6,102 $786,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brown Advisory Inc with notifications on news.

Account

Brown Advisory Inc Vertex Pharmaceuticals Inc Transaction History